@drmitull.bsky.social
Maximum hepatology. Minimum distractions. General Medicine pro max.
Reposted
DECEMBER ISSUE | REVIEW "Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease"
www.nature.com/articles/s41...
#Liversky
www.nature.com/articles/s41...
#Liversky
November 25, 2025 at 9:01 AM
DECEMBER ISSUE | REVIEW "Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease"
www.nature.com/articles/s41...
#Liversky
www.nature.com/articles/s41...
#Liversky
Reposted
Next, Elizabeth Powell charts the momentous changes in #MASLD research and treatment in 2024, from first drug approval to updated guidelines and new biomarkers
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
A new treatment and updated clinical practice guidelines for MASLD - Nature Reviews Gastroenterology & Hepatology
The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatoh...
www.nature.com
November 20, 2024 at 9:15 AM
Next, Elizabeth Powell charts the momentous changes in #MASLD research and treatment in 2024, from first drug approval to updated guidelines and new biomarkers
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky